Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology Associates, PC
mi
from
Nashville, TN
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology Associates, PC
mi
from
Nashville, TN
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Tarrant Nephrology-Arlington
mi
from
Arlington, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Tarrant Nephrology-Arlington
mi
from
Arlington, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
ADC Nephrology
mi
from
Austin, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
ADC Nephrology
mi
from
Austin, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Research Management, Inc
mi
from
Austin, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Research Management, Inc
mi
from
Austin, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Jack Moncrief Group, PA
mi
from
Austin, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Jack Moncrief Group, PA
mi
from
Austin, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Osvaldo A Brusco MD
mi
from
Corpus Christi, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Osvaldo A Brusco MD
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Corsicana Medical Research
mi
from
Corsicana, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Corsicana Medical Research
mi
from
Corsicana, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
North Texas Endocrine Center
mi
from
Dallas, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
North Texas Endocrine Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
UTSWMC at Dallas - Nephrology
mi
from
Dallas, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
UTSWMC at Dallas - Nephrology
mi
from
Dallas, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Sergio F. Rovner, MD
mi
from
El Paso, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Sergio F. Rovner, MD
mi
from
El Paso, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Tarrant Nephrology Associates
mi
from
Fort Worth, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Tarrant Nephrology Associates
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Texas Renal Care
mi
from
Greenville, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Texas Renal Care
mi
from
Greenville, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Southwest Houston Research, Ltd
mi
from
Houston, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Southwest Houston Research, Ltd
mi
from
Houston, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Millenium Clinical Research Inc
mi
from
Houston, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Millenium Clinical Research Inc
mi
from
Houston, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Texas Tech University Health Sciences Center
mi
from
Odessa, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Texas Tech University Health Sciences Center
mi
from
Odessa, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Renal Associates, P.A. Research Division
mi
from
San Antonio, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Renal Associates, P.A. Research Division
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Physicians Clinical Research of San Antonio, PA
mi
from
San Antonio, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Physicians Clinical Research of San Antonio, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Renal Associates PA
mi
from
San Antonio, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Renal Associates PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
San Antonio Kidney Disease Center
mi
from
San Antonio, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
San Antonio Kidney Disease Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Texas Diabetes Institute
mi
from
San Antonio, TX
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Texas Diabetes Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Fletcher Allen Health Care
mi
from
Burlington, VT
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Mendez Center for CLinical Research, LLC
mi
from
Alexandria, VA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Mendez Center for CLinical Research, LLC
mi
from
Alexandria, VA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology Association of Northern Virginia
mi
from
Fairfax, VA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology Association of Northern Virginia
mi
from
Fairfax, VA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Nephrology Specialists, P.C
mi
from
Mechanicsville, VA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Nephrology Specialists, P.C
mi
from
Mechanicsville, VA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Clinical Research Associates of Tidewater
mi
from
Norfolk, VA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Salem VAMC
mi
from
Salem, VA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Salem VAMC
mi
from
Salem, VA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Larry D. Stonesifer, Md
mi
from
Federal Way, WA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Larry D. Stonesifer, Md
mi
from
Federal Way, WA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
MultiCare Research Institute
mi
from
Tacoma, WA
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
MultiCare Research Institute
mi
from
Tacoma, WA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
West Virginia University
mi
from
Morgantown, WV
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated:  9/14/2012
Zablocki VA Medical Center
mi
from
Milwaukee, WI
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)
Status: Enrolling
Updated: 9/14/2012
Zablocki VA Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM
The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.
Status: Enrolling
Updated:  10/1/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM
The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.
Status: Enrolling
Updated: 10/1/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance
Status: Enrolling
Updated:  10/2/2012
VA Eastern Colorado Health Care System, Denver
mi
from
Denver, CO
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation
Effects of PPAR Ligands on Ectopic Fat Accumulation and Inflammation in Subjects With Impaired Glucose Tolerance
Status: Enrolling
Updated: 10/2/2012
VA Eastern Colorado Health Care System, Denver
mi
from
Denver, CO
Click here to add this to my saved trials
Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose
A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes
Status: Enrolling
Updated:  10/2/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose
A Randomized, Controlled Study To Compare the Effects of 2 Types of Dietary Fiber, Psyllium and Microcrystalline Cellulose, on Glycemic Measures in Subjects With Pre-type 2 Diabetes
Status: Enrolling
Updated: 10/2/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)
A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  10/3/2012
Clinical Research Facility
mi
from
Tampa, FL
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)
A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 10/3/2012
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Birmingham, AL
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Fort Smith, AR
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Decatur, GA
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Overland Park, KA
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Metairie, LA
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Jackson, MS
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  10/4/2012
Clinical Research Facility
mi
from
Henderson, NV
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 10/4/2012
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials